Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 15, 2008. The report details a specific corporate action regarding the company's share capital structure.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on share repurchase activity.
- Shares Purchased: 1,100,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,212.70 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.07% of total voting rights).
- Shares in Issue: 5,225,498,484 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of the company's share capital through the cancellation of 1,100,000 shares purchased on September 15, 2008. This transaction was executed under authority granted by shareholders at the Annual General Meeting on May 21, 2008.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Confirm the updated total voting rights denominator (5,225,498,484 shares) for disclosure threshold calculations.
- Verify the total number of Treasury shares held (474,194,158) and the corresponding percentage of voting rights (9.07%).
- Note that the purchased shares were cancelled rather than held indefinitely in treasury.